Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

A T van Oosterom

Showing results (181-190 of 196) with videos related to

Pageof 20
Sort By:
Annals of Oncology : Official Journal of the European Society for Medical Oncology|April 28, 2004
Combination therapy with gefitinib, an epidermal growth factor receptor tyrosine kinase inhibitor, gemcitabine and cisplatin in patients with advanced solid tumorsG Giaccone, J L González-Larriba, A T van Oosterom, et al.
British Journal of Cancer|January 1, 1997
Tumour marker concentration at the start of chemotherapy is a stronger predictor of treatment failure than marker half-life: a study in patients with disseminated non-seminomatous testicular cancerR de Wit, R Sylvester, C Tsitsa, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 16, 2001
Randomized phase III trial of high-dose-intensity methotrexate, vinblastine, doxorubicin, and cisplatin (MVAC) chemotherapy and recombinant human granulocyte colony-stimulating factor versus classic MVAC in advanced urothelial tract tumors: European Organization for Research and Treatment of Cancer Protocol no. 30924C N Sternberg, P H de Mulder, J H Schornagel, et al.
Anti-Cancer Drugs|August 13, 2002
The impact of drug administration sequence and pharmacokinetic interaction in a phase I study of the combination of docetaxel and gemcitabine in patients with advanced solid tumorsH Dumez, M Louwerens, A Pawinsky, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 1, 2005
Phase I and pharmacokinetic study of oral irinotecan given once daily for 5 days every 3 weeks in combination with capecitabine in patients with solid tumorsOtto Soepenberg, Herlinde Dumez, Jaap Verweij, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|July 26, 2003
Real-time quantitative RT-PCR and detection of tumour cell dissemination in breast cancer patients: plasmid versus cell line dilutionsM Saad Ismail, W Wynendaele, J L E Aerts, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 1, 1987
Randomized trial comparing two combination chemotherapy regimens (CHAP-5 v CP) in advanced ovarian carcinomaJ P Neijt, W W ten Bokkel Huinink, M E van der Burg, et al.
European Journal of Cancer (Oxford, England : 1990)|January 1, 1991
Long-term survival in ovarian cancer. Mature data from The Netherlands Joint Study Group for Ovarian CancerJ P Neijt, W W ten Bokkel Huinink, M E van der Burg, et al.
Lancet (London, England)|September 15, 1984
Randomised trial comparing two combination chemotherapy regimens (Hexa-CAF vs CHAP-5) in advanced ovarian carcinomaJ P Neijt, W W ten Bokkel Huinink, M E van der Burg, et al.
European Journal of Cancer (Oxford, England : 1990)|August 31, 2001
Phase II study of mitomycin-C and cisplatin in disseminated, squamous cell carcinoma of the uterine cervix. A European Organization for Research and Treatment of Cancer (EORTC) Gynecological Cancer Group studyH C Wagenaar, S Pecorelli, C Mangioni, et al.
Pageof 20

Showing results (181-190 of 196) with videos related to

Sort By:
Pageof 20
Annals of Oncology : Official Journal of the European Society for Medical Oncology|April 28, 2004
Combination therapy with gefitinib, an epidermal growth factor receptor tyrosine kinase inhibitor, gemcitabine and cisplatin in patients with advanced solid tumorsG Giaccone, J L González-Larriba, A T van Oosterom, et al.
British Journal of Cancer|January 1, 1997
Tumour marker concentration at the start of chemotherapy is a stronger predictor of treatment failure than marker half-life: a study in patients with disseminated non-seminomatous testicular cancerR de Wit, R Sylvester, C Tsitsa, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 16, 2001
Randomized phase III trial of high-dose-intensity methotrexate, vinblastine, doxorubicin, and cisplatin (MVAC) chemotherapy and recombinant human granulocyte colony-stimulating factor versus classic MVAC in advanced urothelial tract tumors: European Organization for Research and Treatment of Cancer Protocol no. 30924C N Sternberg, P H de Mulder, J H Schornagel, et al.
Anti-Cancer Drugs|August 13, 2002
The impact of drug administration sequence and pharmacokinetic interaction in a phase I study of the combination of docetaxel and gemcitabine in patients with advanced solid tumorsH Dumez, M Louwerens, A Pawinsky, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 1, 2005
Phase I and pharmacokinetic study of oral irinotecan given once daily for 5 days every 3 weeks in combination with capecitabine in patients with solid tumorsOtto Soepenberg, Herlinde Dumez, Jaap Verweij, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|July 26, 2003
Real-time quantitative RT-PCR and detection of tumour cell dissemination in breast cancer patients: plasmid versus cell line dilutionsM Saad Ismail, W Wynendaele, J L E Aerts, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 1, 1987
Randomized trial comparing two combination chemotherapy regimens (CHAP-5 v CP) in advanced ovarian carcinomaJ P Neijt, W W ten Bokkel Huinink, M E van der Burg, et al.
European Journal of Cancer (Oxford, England : 1990)|January 1, 1991
Long-term survival in ovarian cancer. Mature data from The Netherlands Joint Study Group for Ovarian CancerJ P Neijt, W W ten Bokkel Huinink, M E van der Burg, et al.
Lancet (London, England)|September 15, 1984
Randomised trial comparing two combination chemotherapy regimens (Hexa-CAF vs CHAP-5) in advanced ovarian carcinomaJ P Neijt, W W ten Bokkel Huinink, M E van der Burg, et al.
European Journal of Cancer (Oxford, England : 1990)|August 31, 2001
Phase II study of mitomycin-C and cisplatin in disseminated, squamous cell carcinoma of the uterine cervix. A European Organization for Research and Treatment of Cancer (EORTC) Gynecological Cancer Group studyH C Wagenaar, S Pecorelli, C Mangioni, et al.
Pageof 20